BIOLQ — November 26, Share Price
0.000.00%
Last trade - 00:00- $0.48m
- $13.42m
- $49.16m
- 29
- 65
- 67
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -29.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 37.8 | 22.78 | 39.19 | 48.46 | 49.16 | 46.6 | 49 | 1.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.
Directors
- Jonathan Lord NEC (66)
- John Beaver PRE (59)
- Kathleen O'Loughlin DRC
- Martha Somerman DRC
- Carol Summerhays DRC
- Michael DiTolla IND (56)
- Richard Lanman IND (66)
- Jess Roper IND (56)
- Garrett Sato IND (60)
- Elaine Wagner IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 10th, 1987
- Public Since
- November 12th, 1992
- No. of Shareholders
- 11
- No. of Employees
- 157
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 36,597,334
- Address
- 27042 Towne Centre Drive, Suite 270, FOOTHILL RANCH, 92610
- Web
- https://www.biolase.com/
- Phone
- +1 9493611200
- Contact
- Michael Polyviou
- Auditors
- BDO USA, LLP
Upcoming Events for BIOLQ
Q1 2025 BIOLASE Inc Earnings Release
Q2 2025 BIOLASE Inc Earnings Release
Similar to BIOLQ
1399 Internet Technology Application
Pink Sheets on Nasdaq
VG Acquisition
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
FAQ
What is the November 26, share price?
As of Today at 01:35 UTC, shares in November 26, are trading at $0.01. This share price information is delayed by 15 minutes.
How has the November 26, share price performed this year?
Shares in November 26, last closed at $0.01 and the price had moved by -91.24% over the past 365 days. In terms of relative price strength the November 26, share price has underperformed the S&P500 Index by -91.88% over the past year.
What are the analyst and broker recommendations for November 26,?
The overall consensus recommendation for November 26, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the November 26, dividend yield?
November 26, does not currently pay a dividend.
Does November 26, pay a dividend?
November 26, does not currently pay a dividend.
When does November 26, next pay dividends?
November 26, does not currently pay a dividend.
How do I buy November 26, shares?
To buy shares in November 26, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of November 26,?
As of the previous close price of $0.01, shares in November 26, had a market capitalisation of $0.48m.
Where are November 26, shares listed?
Here are the trading details for November 26,:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIOLQ
What kind of share is November 26,?
Based on an overall assessment of its quality, value and momentum November 26, is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a November 26, share price forecast for 2025?
The analyst consensus target price for shares in November 26, is $2.00. That is 15284.62% above the last closing price of $0.01.
Analysts covering November 26, currently have a consensus Earnings Per Share (EPS) forecast of -$0.31 for the next financial year.
Find out moreWhat is the trend in the November 26, share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like November 26,. Over the past six months, its share price has outperformed the S&P500 Index by +86.21%.
As of the last closing price of $0.01, shares in November 26, were trading -43.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the November 26, PE Ratio?
The November 26, PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of November 26,?
November 26,'s management team is headed by:
- Jonathan Lord - NEC
- John Beaver - PRE
- Kathleen O'Loughlin - DRC
- Martha Somerman - DRC
- Carol Summerhays - DRC
- Michael DiTolla - IND
- Richard Lanman - IND
- Jess Roper - IND
- Garrett Sato - IND
- Elaine Wagner - IND